Dr James Wilmott

Research Associate
Melanoma Institute Australia, Central Clinical School

Telephone +61 02 9515 7840

Map

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Vilain, R., Wilmott, J., Scolyer, R. (2014). A light shines on melanoma metastagenesis. Pigment Cell and Melanoma Research, 25(7), 696-697. [More Information]
  • Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
  • Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. The Journal of Immunology, 192(5), 2505-2513. [More Information]
  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
  • Dong, L., Jin, L., Tseng, H., Wang, C., Wilmott, J., Yosufi, B., Yan, X., Jiang, C., Jiang, C., Scolyer, R., et al (2014). Oncogenic suppression of PHLPP1 in human melanoma. Oncogene, 33, 4756-4766. [More Information]
  • Wilmott, J., Menzies, A., Haydu, L., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Diemling, A., Scolyer, R., Long, G. (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. British Journal of Cancer, 108(4), 924-931. [More Information]
  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell and Melanoma Research, 26(4), 499-508. [More Information]
  • Long, G., Wilmott, J., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Deimling, A., Scolyer, R. (2013). Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. The American Journal of Surgical Pathology, 37(1), 61-65. [More Information]
  • Ye, Y., Jin, L., Wilmott, J., Hu, W., Yosufi, B., Thorne, R., Liu, T., Rizos, H., Yan, X., Dong, L., Hersey, P., Scolyer, R., et al (2013). PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 4(Article number1508), 1-15. [More Information]
  • Wilmott, J., Haydu, L., Bagot, M., Zhang, Y., Jakrot, V., McCarthy, S., Lugassy, C., Thompson, J., Scolyer, R., Jakrot, V., et al (2012). Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. Histopathology, 61(5), 889-898. [More Information]
  • Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012). Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 1(6), 997-999. [More Information]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
  • Shayan, R., Karnezis, T., Murali, R., Wilmott, J., Ashton, M., Taylor, G., Thompson, J., Hersey, P., Achen, M., Scolyer, R., et al (2012). Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 61(4), 702-710. [More Information]
  • Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012). Selective BRAF inhibitors induce marked T - cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386-1394. [More Information]
  • Cheung, B., Koach, J., Tan, O., Kim, P., Bell, J., D'andreti, C., Sutton, S., Malyukova, A., Sekyere, E., Norris, M., Wilmott, J., Cooper, C., Halliday, G., Scolyer, R., et al (2012). The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. Journal of Pathology, 226(3), 451-462. [More Information]
  • Jin, L., Hu, W., Jiang, C., Wang, J., Han, C., Chu, P., Zhang, L., Thorne, R., Wilmott, J., Scolyer, R., Hersey, P., et al (2011). MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 108(38), 15840-15845. [More Information]
  • Wilmott, J., Zhang, X., Hersey, P., Scolyer, R. (2011). The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology, 43(6), 657-671. [More Information]

Conferences

  • Tallapragada, V., Wilmott, J., Pilowsky, P., Goodchild, A. (2008). A1 and C1 Neurons in the rat brainstem show different profiles of G-a MRNA expression. Australian Neuroscience Society Annul Meeting (2008), Hobart: Australian Neuroscience Society.

2014

  • Vilain, R., Wilmott, J., Scolyer, R. (2014). A light shines on melanoma metastagenesis. Pigment Cell and Melanoma Research, 25(7), 696-697. [More Information]
  • Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
  • Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. The Journal of Immunology, 192(5), 2505-2513. [More Information]
  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
  • Dong, L., Jin, L., Tseng, H., Wang, C., Wilmott, J., Yosufi, B., Yan, X., Jiang, C., Jiang, C., Scolyer, R., et al (2014). Oncogenic suppression of PHLPP1 in human melanoma. Oncogene, 33, 4756-4766. [More Information]

2013

  • Wilmott, J., Menzies, A., Haydu, L., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Diemling, A., Scolyer, R., Long, G. (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. British Journal of Cancer, 108(4), 924-931. [More Information]
  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell and Melanoma Research, 26(4), 499-508. [More Information]
  • Long, G., Wilmott, J., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Deimling, A., Scolyer, R. (2013). Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. The American Journal of Surgical Pathology, 37(1), 61-65. [More Information]
  • Ye, Y., Jin, L., Wilmott, J., Hu, W., Yosufi, B., Thorne, R., Liu, T., Rizos, H., Yan, X., Dong, L., Hersey, P., Scolyer, R., et al (2013). PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 4(Article number1508), 1-15. [More Information]

2012

  • Wilmott, J., Haydu, L., Bagot, M., Zhang, Y., Jakrot, V., McCarthy, S., Lugassy, C., Thompson, J., Scolyer, R., Jakrot, V., et al (2012). Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. Histopathology, 61(5), 889-898. [More Information]
  • Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012). Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 1(6), 997-999. [More Information]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
  • Shayan, R., Karnezis, T., Murali, R., Wilmott, J., Ashton, M., Taylor, G., Thompson, J., Hersey, P., Achen, M., Scolyer, R., et al (2012). Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 61(4), 702-710. [More Information]
  • Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012). Selective BRAF inhibitors induce marked T - cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386-1394. [More Information]
  • Cheung, B., Koach, J., Tan, O., Kim, P., Bell, J., D'andreti, C., Sutton, S., Malyukova, A., Sekyere, E., Norris, M., Wilmott, J., Cooper, C., Halliday, G., Scolyer, R., et al (2012). The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. Journal of Pathology, 226(3), 451-462. [More Information]

2011

  • Jin, L., Hu, W., Jiang, C., Wang, J., Han, C., Chu, P., Zhang, L., Thorne, R., Wilmott, J., Scolyer, R., Hersey, P., et al (2011). MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences (PNAS) of the United States of America, 108(38), 15840-15845. [More Information]
  • Wilmott, J., Zhang, X., Hersey, P., Scolyer, R. (2011). The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology, 43(6), 657-671. [More Information]

2008

  • Tallapragada, V., Wilmott, J., Pilowsky, P., Goodchild, A. (2008). A1 and C1 Neurons in the rat brainstem show different profiles of G-a MRNA expression. Australian Neuroscience Society Annul Meeting (2008), Hobart: Australian Neuroscience Society.

To update your profile click here. For support on your academic profile contact .